By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv
Rybelsus weight loss: what’s the connection?
Rybelsus weight loss is a topic that interests many people with diabetes. It is a pill for type 2 diabetes based on semaglutide, the same active ingredient found in the Ozempic and Wegovy injections. What’s new is that a GLP-1 drug comes as a daily pill taken by mouth. For many people, avoiding injections makes treatment simpler and more accessible. And what about weight? Here the answer is more complex, and I’ll explain it in this article.
How the pill acts on blood sugar and appetite
GLP-1 is a natural hormone that the gut releases after eating. It regulates blood sugar, hunger and fullness. Semaglutide mimics its action. As a result, it boosts insulin release when blood sugar rises, slows stomach emptying and reduces appetite. This combination explains why Rybelsus is not just a drug for blood sugar control. In many people, it also leads to moderate weight loss.
Who the drug is for
Rybelsus is intended for adults with type 2 diabetes. Doctors prescribe it as part of a comprehensive program, with a tailored diet and physical activity. The drug is not approved for treating obesity without diabetes. In addition, it is not suitable for type 1 diabetes.
For a broader look at the drug itself, see my full guide to Rybelsus treatment for diabetes and weight.
What the studies showed on blood sugar and the heart
The PIONEER research program tested Rybelsus in people with diabetes. In the PIONEER 1 trial, the 14 mg dose lowered HbA1c, the average blood sugar over the past three months, by 1.1% more than placebo. In addition, the SOUL trial included 9,650 people with diabetes at high heart risk. A major heart event occurred in 12.0% of patients on Rybelsus, compared with 13.8% on placebo. Following these results, the US Food and Drug Administration (FDA) added an indication for lowering heart risk.
Rybelsus weight loss: the numbers
Weight loss with Rybelsus is moderate. PIONEER 1 showed a difference of 2.3 kg versus placebo after 26 weeks. In the PIONEER 4 trial, by contrast, patients on the pill lost 4.4 kg on average. In other words, most patients lose a few kilograms, but not dozens.
The reason is simple: the doses target blood sugar control, not obesity. The proof came from the PIONEER PLUS trial. In this trial, 1,606 people with diabetes received doses of 14, 25 or 50 mg. Their weight dropped by 4.4 kg on 14 mg, 6.7 kg on 25 mg and 8.0 kg on 50 mg. However, the trial tested the higher doses as experimental doses, and they are not part of Rybelsus treatment.
What affects success with weight
Many patients describe less hunger and less snacking. Still, the number of kilograms lost depends on several factors. First, taking the pill correctly and consistently. Second, changes in diet and activity. Finally, blood sugar control itself also changes the picture. Therefore, Rybelsus and weight loss go well together when the drug is part of a broader program. My article on obesity and type 2 diabetes explains the link between the two in more depth.
Rybelsus weight loss starts with taking it correctly
How you take the pill is a small but critical detail for success. Take it in the morning on an empty stomach, with up to 120 ml of water. Then wait at least half an hour before eating, drinking or taking other medications. This improves absorption. In addition, the doses in the new formulation are 1.5, 4 and 9 mg, instead of 3, 7 and 14 mg. The UK medicines regulator warned about dosing errors during the transition period. So it is important to check the equivalent dose with your doctor and pharmacist.
Side effects to know about
The common side effects involve the digestive system: nausea, diarrhea, constipation and a feeling of fullness. In most cases, they are temporary and ease as the body adapts or as the doctor adjusts the dose. In PIONEER PLUS, for example, digestive side effects occurred in 42% of patients on 14 mg. On 25 and 50 mg, the rate rose to 53% and 54%.
There are also rare risks shared by the entire GLP-1 family, such as pancreatitis and gallstones. According to the FDA prescribing information, the drug caused thyroid tumors in rodents. For this reason, anyone with a personal or family history of medullary thyroid cancer must not take it. Because of these risks, treatment takes place under medical supervision. You’ll find a broad overview in my article on the side effects of weight-loss drugs.
Why even a few kilograms matter
Many people with diabetes feel disappointed by a loss of four or five kilograms. Even so, moderate weight loss also improves the body’s sensitivity to insulin. Moreover, it eases blood pressure and blood fats. In other words, every kilogram counts. The Look AHEAD study, for example, examined the effect of weight loss in people with diabetes over many years. I describe it in detail in my article on the lessons of the Look AHEAD trial.
When weight is the main goal
When the main goal is substantial weight loss, Rybelsus is usually not the first choice. In such cases, we consider a dedicated obesity treatment. One option is the Wegovy pill, semaglutide at a dose of 25 mg. There are also injectable options, for example Wegovy for people with diabetes.
The bottom line on Rybelsus weight loss
Rybelsus is a significant step forward in diabetes care. It controls blood sugar with a daily pill, protects the heart and usually contributes to moderate weight loss. On the other hand, you should not expect the results of a dedicated obesity drug. Ultimately, Rybelsus and weight loss go hand in hand mainly when treatment includes nutrition, movement and follow-up. We make the choice after a medical evaluation, based on each patient’s needs, health status and goals.
The information in this article is general and does not replace personal medical advice.
References
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
RYBELSUS (semaglutide) tablets – Prescribing Information
Rybelsus (semaglutide tablets): transition to new formulation and risk of medication error
Novo Nordisk, the drug’s manufacturer, funded the studies.
